In conclusion, LINC00665 may be an important driver of cancer cell resistance to gefitinib, cisplatin, and gemcitabine, and has the potential to predict the efficacy of cisplatin-paclitaxel neoadjuvant chemotherapy. The gene discussed is LINC00665; the disease is cancer.